Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Open access

Abstract

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3–9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0–9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7–10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6–34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1–7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05–2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01–1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01536-x

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Trial flow chart. Breakdown of patients in study. *For two patients in the placebo group, no data were available on adherence with study medication at 12 weeks.
Fig. 1 Trial flow chart. Breakdown of patients in study. *For two patients in the placebo group, no data were available on adherence with study medication at 12 weeks.CC BY · PubMed Central
Fig. 2 Effects of dapagliflozin on the primary endpoint and its components. a–d, Effects of dapagliflozin on the primary endpoint and its components. Effects of dapagliflozin versus placebo at 12 weeks on KCCQ-CS (a), KCCQ-TS (b), KCCQ-physical limitations score (KCCQ-PL) (c) and KCCQ-CS by subgroup (d). Units for loop diuretic dose (d), mg furosemide equivalents. Data are presented as mean values with 95% CI. a–c, An F-test was used in the data analysis. All P values are two-sided, with no adjustments made for multiple comparisons.
Fig. 2 Effects of dapagliflozin on the primary endpoint and its components. a–d, Effects of dapagliflozin on the primary endpoint and its components. Effects of dapagliflozin versus placebo at 12 weeks on KCCQ-CS (a), KCCQ-TS (b), KCCQ-physical limitations score (KCCQ-PL) (c) and KCCQ-CS by subgroup (d). Units for loop diuretic dose (d), mg furosemide equivalents. Data are presented as mean values with 95% CI. a–c, An F-test was used in the data analysis. All P values are two-sided, with no adjustments made for multiple comparisons.CC BY · PubMed Central
Fig. 3 Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. a–c, Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. Effects of dapagliflozin versus placebo at 12 weeks on 6MWT distance (a), KCCQ-CS responder analysis (b) and KCCQ-OS (c). Data are presented as mean values with 95% CI. a,c, An F-test was used in data analysis; b, a chi-square test was used in data analysis All P values are two-sided, with no adjustments made for multiple comparisons.
Fig. 3 Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. a–c, Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. Effects of dapagliflozin versus placebo at 12 weeks on 6MWT distance (a), KCCQ-CS responder analysis (b) and KCCQ-OS (c). Data are presented as mean values with 95% CI. a,c, An F-test was used in data analysis; b, a chi-square test was used in data analysis All P values are two-sided, with no adjustments made for multiple comparisons.CC BY · PubMed Central
Extended Data Fig. 1 Map of the study sites.
Extended Data Fig. 1 Map of the study sites.CC BY · PubMed Central
Extended Data Fig. 2 Trial design and schedule of study visits.
Extended Data Fig. 2 Trial design and schedule of study visits.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 701

Metadata

Authors
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., Lamba, S., Sharma, K., Khan, S. S., Chandra, L., Gordon, R. A., Ryan, J. J., Chaudhry, S.-P., Joseph, S. M., Chow, C. H., Kanwar, M. K., Pursley, M., Siraj, E. S., Lewis, G. D., Clemson, B. S., Fong, M., & Kosiborod, M. N.
Affiliations
  • Saint Luke's Hospital (US)
  • Mayo Clinic (US)
  • Wake Forest University Health Sciences (US)
  • Northwestern University (US)
  • Emory University (US)
  • First Coast Cardiovascular Institute (US)
  • Johns Hopkins University (US)
  • Endeavor Health (US)
  • University of Utah (US)
  • University of Maryland, Baltimore (US)
  • Stormont Vail Health (US)
  • Allegheny Health Network (US)
  • Eastern Virginia Medical School (US)
  • Massachusetts General Hospital (US)
  • OSF HealthCare (US)
  • University of Southern California (US)
  • UNSW Sydney (AU)
Corresponding author
Kosiborod, Mikhail N.
Venue
Nature Medicine
Published
2021-10-28
Volume
27
Issue
11
Pages
1954-1960
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3210475044
Cited by
618
References
38
Citations by year
2026: 68 · 2025: 89 · 2024: 149 · 2023: 140 · 2022: 165 · 2021: 7
FWCI
77.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • AstraZeneca
  • University of Pennsylvania
  • Saint Luke's Health System
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
heart failure with preserved ejection fraction, dapagliflozin, SGLT2 inhibitors, Kansas City Cardiomyopathy Questionnaire, health-related quality of life, symptom burden, physical limitations, 6-minute walk test, weight loss, natriuretic peptides, HbA1c, systolic blood pressure, cardiometabolic abnormalities, heart failure treatment
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Double-Blind Method, Female, Glucosides, Health Status, Heart Failure, Humans, Male, Middle Aged, Placebos, Quality of Life, Surveys and Questionnaires, Stroke Volume, Exercise, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. https://app.cochat.ai/papers/10.1038/s41591-021-01536-x
The paper
Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., Lamba, S., Sharma, K., Khan, S. S., Chandra, L., Gordon, R. A., Ryan, J. J., Chaudhry, S.-P., Joseph, S. M., Chow, C. H., . . . Kosiborod, M. N. (2021). The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01536-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.